BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36394520)

  • 1. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.
    Soni UK; Wang Y; Pandey RN; Roberts R; Pressey JG; Hegde RS
    Clin Cancer Res; 2023 Jan; 29(2):458-471. PubMed ID: 36394520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth.
    Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
    Cancer Res; 2021 Jan; 81(2):501-514. PubMed ID: 33158816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe.
    Martin JC; Sims JR; Gupta A; Bakin AV; Ohm JE
    Cancer Res Commun; 2022 Jun; 2(6):471-482. PubMed ID: 36338546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
    Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
    PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis.
    Martins AS; Ordóñez JL; Amaral AT; Prins F; Floris G; Debiec-Rychter M; Hogendoorn PC; de Alava E
    PLoS One; 2011; 6(5):e19846. PubMed ID: 21611203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis.
    Pasello M; Giudice AM; Cristalli C; Manara MC; Mancarella C; Parra A; Serra M; Magagnoli G; Cidre-Aranaz F; Grünewald TGP; Bini C; Lollini PL; Longhi A; Donati DM; Scotlandi K
    Cell Oncol (Dordr); 2022 Dec; 45(6):1237-1251. PubMed ID: 36149602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
    Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
    Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.
    Mackintosh C; García-Domínguez DJ; Ordóñez JL; Ginel-Picardo A; Smith PG; Sacristán MP; de Álava E
    Oncogene; 2013 Mar; 32(11):1441-51. PubMed ID: 22641220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
    Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
    Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 18. Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers.
    Yang C; Zhang Y; Chen Y; Ragaller F; Liu M; Corvigno S; Dahlstrand H; Carlson J; Chen Z; Näsman A; Waraky A; Lin Y; Larsson O; Haglund F
    PLoS One; 2020; 15(7):e0236291. PubMed ID: 32701997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
    Agelopoulos K; Richter GH; Schmidt E; Dirksen U; von Heyking K; Moser B; Klein HU; Kontny U; Dugas M; Poos K; Korsching E; Buch T; Weckesser M; Schulze I; Besoke R; Witten A; Stoll M; Köhler G; Hartmann W; Wardelmann E; Rossig C; Baumhoer D; Jürgens H; Burdach S; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Nov; 21(21):4935-46. PubMed ID: 26179511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.